# US 2020/0400684 A1 · Nourin gene-based rna molecular network: novel early diagnostic and prognostic biomarkers for coronary artery disease, unstable angina, stemi/nstemi and heart failure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0400684 A1
- Document ID: US20200400684A1
- Status: Published application
- Kind: A1
- Application number: 16/948,240
- Filed: 2020-09-09
- Published: 2020-12-24
- Earliest claimed: 2018-06-18
- Assignees: Nour Heart, Inc.
- Applicants: Nour Heart, Inc.
- Inventors: Salwa A. Elgebaly
- Web page: https://patentgrep.com/patent/US20200400684A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/141: MicroRNAs, miRNAs
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- G01N 2800/324: Coronary artery diseases, e.g. angina pectoris, myocardial infarction
- G01N 2800/325: Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention provides a method for the early diagnosis, prognosis and differentiation of ischemic cardiac events in myocardial ischemia by a Nourin gene-based RNA molecular network of biomarkers to: (a) diagnose unstable angina and AMI (STEMI and NSTEMI) patients, and differentiate between unstable angina and AMI; (b) diagnose ACS patients and differentiate them from symptomatic non-cardiac patients and healthy subjects; (c) diagnose angina in suspected patients with history of chest pain and differentiate angina patients from symptomatic non-angina and healthy subjects; and (d) diagnose “new-onset” heart failure and provide a prognostic value and risk prediction of progression and deterioration, as well as monitoring patients' response to treatments. Downregulation of Nourin-related lncR-CTB9H12.4 in ischemic heart disease patients compared to symptomatic non-cardiac and healthy subjects, is significantly associated with upregulation of hsa-miR-137 and hsa-miR-106b, and overexpression of mRNA-FTHL-17 and mRNA-ANAPC11, respectively, that results in upregulation of Nourin gene and protein network.

## Claims

### Claim 1

A method for the early diagnosis, prognosis and differentiation of ischemic cardiac events in myocardial ischemia by a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence, comprising:
obtaining a sample from a subject; and
assaying the sample for one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence, comprising:
i) anaphase promoting complex subunit mRNA-11 (mRNA-ANAPC11) gene;
ii) ferritin heavy chain like polypeptide mRNA-17 (mRNA-FTHL-17) gene;
iii) Homo sapiens micro RNA-106b (hsa-miRNA-106b);
iv) Homo sapiens micro RNA-137 (hsa-miRNA-137);
v) Nourin gene mRNA (mRNA-Nourin); and
vi) long non-coding intergenic RNA (lnc-RNA-CTB89H12.4),
wherein, hsa-miRNA-137 is a marker of cell damage,
wherein, hsa-miRNA-106b is a marker of cardiovascular inflammation,
wherein, hsa-miRNA-137 and hsa-miRNA-106b regulate the expression of Nourin gene and are linked to myocardial ischemia and ischemic cardiac events,
wherein, hsa-miRNA-137 and hsa-miRNA-106b are upregulated after ischemic cardiac events in myocardial ischemia and are linked to overexpression of mRNA-FTHL-17 and mRNA-ANAPC11,
wherein, hsa-miRNA-137 and hsa-miRNA-106b are upstream regulated by lnc-RNA-CTB89H12.4,
wherein, lnc-RNA-CTB89H12.4 is downregulated after ischemic cardiac events in myocardial ischemia and is linked to higher levels of hsa-miRNA-137 and hsa-miRNA-106b, and to overexpression of mRNA-FTHL-17 and mRNA-ANAPC11,
wherein, lnc-RNA-CTB89H12.4 is downregulated after ischemic cardiac events in myocardial ischemia and is linked to increased translation and production of high levels of Nourin protein,
wherein, hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and Nourin protein show extremely low or no expression in the samples from healthy, non-ischemic, non-cardiac subject, and
wherein, lnc-RNA-CTB89H12.4 is upregulated in the samples from healthy, non-ischemic, non-cardiac subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein assaying the sample for one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence diagnoses suspected angina in stable coronary artery disease patients with a history of chest pain and differentiates angina from non-angina patients, and from healthy subjects, wherein,
a high hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene expression level and combination thereof, in a subject with positive ECHO/ECG Treadmill stress test diagnoses presence of myocardial ischemia in angina patients experiencing chest pain with negative Troponin, a high hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene expression level and combination thereof, in angina patients before ECHO/ECG Treadmill stress test in a subject, wherein the elevated gene expression correlates with the positive stress test in the subject and diagnoses myocardial ischemia in angina patients,
a high hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene expression level and combination thereof, in angina patients 30 minutes after ECHO/ECG Treadmill stress test in a subject, wherein the elevated gene expression correlates with the positive stress test in the subject and diagnoses myocardial ischemia in angina patients,
no difference in high hsa-miRNA-137 gene expression level before and after ECHO/ECG Treadmill stress test in the subject, wherein the elevated gene expression correlates with the positive stress test in the subject and diagnoses myocardial ischemia in angina patients,
higher hsa-miRNA-106b gene expression after ECHO/ECG Treadmill stress test compared to before in the subject with positive stress test and diagnoses myocardial ischemia in angina patients,
no elevation of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene expression level and combination thereof, in negative ECHO/ECG Treadmill stress test in the subject is indicative of absence of ischemic cardiac event and myocardial ischemia in symptomatic non-angina patients with negative Troponin and differentiates symptomatic non-angina patients from angina patients,
no elevation of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene expression level and combination thereof, before ECHO/ECG Treadmill stress test, and wherein the lack of elevation of gene expression correlates with the negative stress test in the subject is indicative of non-ischemic events and differentiates non-angina patients with chest pain from angina patients,
no elevation of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene expression level and combination thereof, in symptomatic non-angina patients 30 minutes after ECHO/ECG Treadmill stress test, wherein the lack of elevation of gene expression correlates with the negative stress test in the subject is indicative of non-ischemic events and differentiates non-angina patients with chest pain from angina patients,
no difference in lack of elevation of hsa-miRNA-137 and hsa-miRNA-106b gene expression level before and after the negative ECHO/ECG Treadmill stress test in symptomatic subject is indicative for non-angina patients, and
no elevation of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene expression level and combination thereof,
in healthy individuals 30 minutes after the ECHO/ECG Treadmill stress test, wherein the lack of elevation of gene expression level correlates with the negative stress test and is indicative of absence of ischemic cardiac event and myocardial ischemia and differentiates healthy subjects from angina patients.

### Claim 3 (depends on 1)

The method of claim 1, wherein assaying the sample for one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence is a non-invasive, fast, diagnostic and prognostic assay for ischemic cardiac events in myocardial ischemia in stable coronary artery disease patients as seen in outpatient clinics, comprising:
a) identifying angina in the subject suspected to being a stable coronary artery disease patient as seen in the outpatient clinics with chest pain in terms of ischemic cardiac events in myocardial ischemia with the assay of one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence selected from the group consisting of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof, in the sample from the subject;
b) identifying ischemic cardiac events in myocardial ischemia in outpatient clinics during routine physical visits in terms of ischemic cardiac events in myocardial ischemia with the assay of one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence selected from the group consisting of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof, in the sample from the subject;
c) identifying myocardial ischemia patients at-risk for coronary artery disease in terms of ischemic cardiac events in myocardial ischemia with the assay of one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence selected from the group consisting of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof, in the sample from the subject;
d) identifying a subject who experienced microvascular angina that otherwise would be missed by current coronary angiography procedure and ECHO/ECG Treadmill stress test in terms of ischemic cardiac events in myocardial ischemia with the assay of one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence selected from the group consisting of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof, in the sample from the subject;
e) differentiating angina patients from non-angina patients with chest pain in terms of ischemic cardiac events in myocardial ischemia with the assay of one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence selected from the group consisting of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof, in the sample from the subject;
f) differentiating angina from non-ischemic healthy subjects in terms of ischemic cardiac events in myocardial ischemia with the assay of one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence selected from the group consisting of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof, in the sample from the subject; and
g) differentiating angina from non-cardiac patients with chest pain and non-ischemic, non-stressed healthy individuals to prevent unnecessary hospitalization, treatment, and medical costs.

### Claim 4 (depends on 1)

The method of claim 1, wherein assaying the sample for one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence diagnoses unstable angina patients at presentation to hospital Emergency Department (ED), comprising:
a) assaying the sample for gene expression level of one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence selected from the group consisting of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof;
b) assaying Troponin level in the sample;
c) performing invasive coronary angiography and other procedures for diagnosing myocardial ischemia;
d) correlating the gene expression level of step (a) with Troponin level of step (b);
e) correlating the gene expression level of step (a) with the invasive coronary angiography and other procedures for diagnosing myocardial ischemia of step (c);
f) monitoring heart health and disease management of unstable angina patients after medical treatment and intervention procedures; and
g) monitoring disease progression from unstable angina to acute myocardial infarction and heart failure,
wherein a high gene expression level obtains an early diagnosis of unstable angina patients experiencing acute chest pain in the subject at presentation to the ED when Troponin level is below the clinical decision (below the 99th percentile upper reference limit (URL)),
wherein no elevation of gene expression in the sample from the subject identifies healthy subjects,
wherein a higher hsa-miRNA-137 gene expression level of 1,185-fold increase is obtained in diagnosed unstable angina patients in comparison to healthy individuals and differentiates the subject with unstable angina patients and chest pain at presentation to the ED from healthy individuals,
wherein a higher hsa-miRNA-106b gene expression level of 150-fold increase is obtained in diagnosed unstable angina patients in comparison to healthy individuals and differentiates the subject with unstable angina patients and chest pain at presentation to the ED from healthy individuals, and
wherein an elevated gene expression level in unstable angina patients correlates with positive results from invasive coronary angiography in diagnosing myocardial ischemia.

### Claim 5 (depends on 1)

The method of claim 1, wherein assaying the sample for one or more of a Nourin gene-based RNA molecular network and Nourin protein, of biomarkers related to the Nourin peptide sequence diagnoses ST elevation myocardial infarction (STEMI) patients at presentation to hospital Emergency Department (ED):
a) assaying the sample for gene expression level of one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence selected from the group consisting of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof;
b) assaying Troponin level in the sample;
c) performing invasive coronary angiography for presence of coronary artery thrombosis for diagnosing positive STEMI patients;
d) performing ECG for diagnosing positive ischemic changes;
e) correlating the gene expression level of step (a) with Troponin level of step (b);
f) correlating the gene expression level from step (a) with the invasive coronary angiography for diagnosing myocardial ischemia of step (c);
g) correlating the gene expression level of step (a) with the positive ischemic changes diagnosed by ECG of step (d);
h) monitoring heart health and disease management of STEMI patients after medical treatment and intervention procedures;
i) screening STEMI patients for risk assessment to predict which patients are at risk for developing heart failure; and
j) monitoring disease progression from STEMI to heart failure,
wherein a high gene expression level obtains an early diagnosis of STEMI experiencing chest pain in the subject at presentation to the ED when Troponin level is above or below the clinical decision,
wherein a high gene expression level obtains an early diagnosis of STEMI experiencing acute chest pain in the subject at presentation to the ED with positive or negative ischemic changes diagnosed by ECG,
wherein no elevation of gene expression in the sample from the subject identifies healthy subjects,
wherein a higher hsa-miRNA-137 gene expression level of 3,011-fold increase is obtained in diagnosed STEMI patients experiencing acute chest pain in comparison to healthy individuals and differentiates the subjects as STEMI patients experiencing chest pain at presentation to the ED from healthy individuals,
wherein a higher hsa-miRNA-106b gene expression level of 688-fold increase is obtained in diagnosed STEMI patients experiencing chest pain in comparison to healthy individuals and differentiates the subjects as STEMI patients experiencing chest pain at presentation to the ED from healthy individuals,
wherein an elevated gene expression level in STEMI patients correlates with positive ischemic changes diagnosed by ECG,
wherein an elevated gene expression level in STEMI patients correlates with positive Troponin level above the clinical decision, and
wherein an elevated gene expression level in STEMI patients correlates with positive disease diagnosis by invasive coronary angiography for presence of coronary artery thrombosis in diagnosing STEMI patients.

### Claim 6 (depends on 1)

The method of claim 1, wherein assaying the sample for one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence diagnoses non-ST elevation myocardial infarction (NSTEMI) patients at presentation to hospital Emergency Department (ED):
a) assaying the sample for gene expression level of one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence selected from the group consisting of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof;
b) assaying Troponin level in the sample;
c) performing invasive coronary angiography for presence of coronary artery thrombosis for diagnosing positive NSTEMI patients;
d) correlating the gene expression level of step (a) with Troponin level of step (b);
e) correlating the gene expression level of step (a) with the invasive coronary angiography for diagnosing myocardial ischemia of step (c);
f) monitoring heart health and disease management of NSTEMI patients after medical treatment and intervention procedures;
g) screening NSTEMI patients for risk assessment to predict which patients are at risk for developing heart failure; and
h) monitoring disease progression from NSTEMI to heart failure,
wherein a high gene expression level obtains an early diagnosis of NSTEMI experiencing acute chest pain in the subject at presentation to the ED when Troponin level is above or below the clinical decision,
wherein a high gene expression level obtains an early diagnosis of NSTEMI experiencing chest pain in the subject at presentation to the ED with negative ischemic changes diagnosed by ECG,
wherein no elevation of gene expression in the sample from the subject identifies healthy subjects,
wherein a higher hsa-miRNA-137 gene expression level of 10-fold increase is obtained in diagnosed NSTEMI patients experiencing chest pain in comparison to healthy individuals and differentiates the subjects as NSTEMI patients experiencing chest pain at presentation to the ED from healthy subjects,
wherein the high gene expression level is similar in STEMI and NSTEMI patients,
wherein an elevated gene expression level in NSTEMI patients correlates with positive Troponin level above the clinical decision (above the 99th of URL), and
wherein an elevated gene expression level in NSTEMI patients correlates with positive disease diagnosis by invasive coronary angiography for presence of coronary artery thrombosis in diagnosing NSTEMI patients.

### Claim 7 (depends on 1)

The method of claim 1, wherein assaying the sample for one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence discriminates and differentiates unstable angina patients from healthy individuals, comprising:
a) identifying the subject who experienced unstable angina, wherein the Nourin gene expression is much higher in unstable angina than healthy subjects with an increase of 1,185-fold for hsa-miRNA-137 and 150-fold for hsa-miRNA-106b;
b) discriminating and differentiating unstable angina from healthy subjects in terms of hsa-miRNA-137 gene expression level at a test sensitivity of 97% and specificity of 94%, and at a cutoff of 195.4; and
c) discriminating and differentiating unstable angina from healthy subjects in terms of hsa-miRNA-106b with a test sensitivity of 87% and specificity of 88%, and at a cutoff of 90.4.

### Claim 8 (depends on 1)

The method of claim 1, wherein assaying the sample for one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence discriminates and differentiates STEMI and NSTEMI patients from healthy subjects, in terms of hsa-miRNA-137 with a test sensitivity of 98.5% and specificity of 96.8%.

### Claim 9 (depends on 1)

The method of claim 1, wherein assaying the sample for one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence discriminates and differentiates unstable angina patients from STEMI and NSTEMI patients at presentation to hospital Emergency Department (ED):
a) identifying the subject who experienced unstable angina, wherein the Nourin gene expression of hsa-miRNA-137 is much higher with 2.5-fold increase in STEMI and NSTEMI than unstable angina subjects;
b) identifying the subject who experienced unstable angina, wherein the Nourin gene expression of hsa-miRNA-106b is much higher with 4.6-fold increase in STEMI and NSTEMI than unstable angina subjects;
c) discriminating and differentiating unstable angina from STEMI in terms of hsa-miRNA-137 with a test sensitivity of 75% and specificity of 83%, and at a cutoff of 2,488; and
d) discriminating and differentiating unstable angina from STEMI in terms of hsa-miRNA-106b with a test sensitivity of 86% and specificity of 90%, and at a cutoff of 385;
wherein the gene expression level is an independent risk factor for identification of ischemic cardiac events in myocardial injury in stable coronary artery disease, unstable angina, acute myocardial infarction patients (STEMI and NSTEMI) and patients undergoing cardiac surgery with hsa-miRNA-137 and hsa-miRNA-106b having high sensitivity and specificity for the identification of ischemic cardiac events in myocardial injury.

### Claim 10 (depends on 1)

The method of claim 1, wherein the obtained gene expression level of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene expression level and the combination thereof, by assaying the sample for one or more of a Nourin gene-based RNA molecular network and Nourin protein, of biomarkers related to the Nourin peptide sequence is associated with severity estimation of ischemic cardiac events in myocardial ischemia, wherein,
a) absence or baseline gene expression level in samples from healthy subjects is associated with absence of ischemic cardiac events in myocardial ischemia and are negative for myocardial ischemia;
b) absence or baseline gene expression level in samples from symptomatic non-ischemic patients with negative ECHO/ECG Treadmill stress test have gene expression level comparable to healthy subjects with absence of ischemic cardiac events in myocardial ischemia and are negative for myocardial ischemia;
c) absence or baseline gene expression level in samples from symptomatic non-ACS patients at presentation to hospital ED have gene expression level comparable to healthy subjects with absence of ischemic cardiac events in myocardial ischemia and are negative for myocardial ischemia;
and wherein, elevated gene expression level is positively correlated with the severity of myocardial ischemia, and the severity estimation of myocardial ischemia is determined as low, moderate and severe, wherein,
d) coronary artery disease patients have gene expression level that identify patients with low to moderate myocardial ischemia severity;
e) 70% of unstable angina patients who had known coronary artery disease and progressed to experience unstable angina have gene expression level that identify patients with moderate myocardial ischemia severity;
f) unstable angina patients at presentation to hospital ED have gene expression level that identify patients with moderate myocardial ischemia severity; and
g) STEMI and NSTEMI patients at presentation to hospital ED have gene expression level that identify patients with severe myocardial ischemia severity.

### Claim 11 (depends on 1)

The method of claim 1, wherein by assaying the sample for one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence, the obtained gene expression level of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene expression level and Nourin protein, and combination thereof provides the severity estimation of myocardial ischemia, wherein the estimated severity:
a) screens at-risk patients for development of coronary artery disease patients,
b) identifies stable coronary artery disease patients with moderate to severe ischemia, who will benefit from the invasive percutaneous coronary intervention before conducting the procedure,
c) identifies stable coronary artery disease patients with low to mild ischemia, who will not benefit from the invasive percutaneous coronary intervention before conducting the procedure and whom they would benefit from medical therapy,
d) screens stable coronary artery disease patients for risk assessment to predict which patients are at risk for developing unstable angina and acute myocardial infarction,
e) screens patients for cardiovascular inflammation and myocarditis,
f) indicates myocardial ischemia severity of low, moderate, and severe, as a risk assessment tool to predict which unstable angina patients are at risk for developing acute myocardial infarction,
g) rules in and rules out a subject as an unstable angina patient,
h) rules in and rules out a subject as an acute myocardial infarction patient (STEMI and NSTEMI),
i) indicates risk stratification of acute myocardial infarction patients, and
j) identifies symptomatic ACS patients comprising, unstable angina and acute myocardial infarction patients for discrimination and differentiation from symptomatic non-cardiac patients and healthy subjects.

### Claim 12 (depends on 1)

The method of claim 1, wherein assaying the sample for one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence diagnoses subclinical, silent myocardial ischemia, and low-grade myocardial ischemia.

### Claim 13 (depends on 1)

The method of claim 1, wherein assaying the sample for one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence diagnoses microvascular angina not identified by current invasive procedures.

### Claim 14 (depends on 1)

The method of claim 1, wherein assaying the sample for one or more of a Nourin gene-based RNA molecular network and Nourin protein, of biomarkers related to the Nourin peptide sequence accelerates the diagnosis of unstable angina and acute myocardial infarction (STEMI and NSTEMI) patients at presentation to hospital Emergency Department (ED) into:
a subject who experienced unstable angina, wherein the Nourin gene expression is high at presentation, when Troponin level is below the clinical decision (below the 99th of URL);
a subject who experienced ST elevation myocardial infarction (STEMI), wherein the Nourin gene expression is high at presentation, when Troponin level is below the clinical decision (below the 99th of URL);
a subject who experienced non-ST elevation myocardial infarction (NSTEMI), wherein the Nourin gene expression is high at presentation, when negative ischemic changes diagnosed by ECG;
a subject who experienced non-ST elevation myocardial infarction (NSTEMI), wherein the Nourin gene expression is high at presentation, when Troponin level is below the clinical decision (below the 99th of URL); and
a subject who experienced non-ST elevation myocardial infarction (NSTEMI), wherein the Nourin gene expression is high at presentation, when Troponin level is above the clinical decision (above the 99th of URL),
wherein, Nourin gene expression is high at presentation to the ED without additional need for waiting as required by Troponin, and discriminates and differentiates unstable angina, STEMI, and NSTEMI patients at presentation to the ED from symptomatic non-cardiac patients and healthy subjects for an early and accelerated diagnosis.

### Claim 15 (depends on 1)

The method of claim 1, wherein assaying the sample for one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence diagnoses heart failure, comprising:
a) assaying the sample for gene expression level of one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence selected from the group consisting of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof;
b) assaying the sample for level of the cardiac marker CK-MB;
c) assaying the sample for gene expression level of lncR-CTB89H12.4, a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence;
d) assessing the subject for amount of collagen deposition;
e) assessing the subject for amount of fibrosis;
f) assessing the subject for heart weight;
g) assessing the subject for amount of ejection fraction;
h) assessing the subject for physical activity level;
i) correlating the gene expression level of step (a) with the gene expression level of the cardiac marker CK-MB of step (b);
j) correlating the gene expression level of step (a) with the gene expression level of the lncR-CTB89H12.4 of step (c);
k) correlating the gene expression level of step (a) with the amount of collagen deposition of step (d);
l) correlating the gene expression level of step (a) with the amount of fibrosis of step (e);
m) correlating the gene expression level of step (a) with the heart weight of step (f);
n) correlating the gene expression level of step (a) with the amount of ejection fraction of step (g); and
o) correlating the gene expression level of step (a) with the physical activity level of step (h),
wherein, a high gene expression level in step (a) diagnoses ischemia-induced heart failure,
wherein the gene expression elevation in step (a) is not elevated under healthy non-ischemic conditions,
wherein, a higher gene expression level in step (a) of 8.91-fold increase is obtained to diagnose ischemia-induced heart failure in comparison to healthy non-ischemic conditions,
wherein, a positive correlation in step (i) is associated with myocardial injury,
wherein the elevated gene expression level in step (a) is associated with increase in cardiac marker CK-MB in step (b),
wherein, a negative correlation in step (j) is associated with myocardial injury,
wherein the elevated gene expression level in step (a) is associated with downregulation of lncR-CTB89H12.4 in step (c),
wherein, a positive correlation in step (k) is associated with myocardial injury,
wherein the elevated gene expression level in step (a) is associated with an increase in collagen deposition in step (d),
wherein, a positive correlation in step (1) is associated with myocardial injury,
wherein the elevated gene expression level in step (a) is associated with an increase in fibrosis in step (e),
wherein, a positive correlation in step (m) is associated with myocardial injury,
wherein the elevated gene expression level in step (a) is associated with an increase in heart weight in step (f),
wherein, a negative correlation in step (n) is associated with myocardial injury and cardiac function, wherein the elevated gene expression level in step (a) is associated with a drop in ejection fraction in step (g),
wherein, a negative correlation in step (o) is associated with myocardial injury and cardiac function, wherein the elevated gene expression level in step (a) is associated with low physical activity in step (h), and
wherein, downregulation of lncR-CTB89H12.4 resulted in up-regulation of hsa-miRNA-137 and hsa-miRNA-106b which activated mRNA-FTHL-17 and mRNA-ANAPC11, resulting in an increase in translation of the Nourin protein.

### Claim 16 (depends on 1)

The method of claim 1, wherein assaying the sample for one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence predicts heart failure after myocardial ischemia and monitors disease progression, comprising:
a) assaying the sample for gene expression level of one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence selected from the group consisting of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof;
b) diagnosing acute and chronic heart failure and asymptomatic heart failure with the gene expression level of step (a);
c) determining severity of heart damage after myocardial ischemia with the gene expression level of step (a);
d) diagnosing heart failure patients after acute myocardial infarction with the gene expression level of step (a);
e) predicting heart failure in patients after myocardial ischemia and rule in or rule out patients for advancement to heart failure with the gene expression level of step (a);
f) monitoring disease progression of heart failure patients with the gene expression level of step (a);
g) providing a prognostic value for new-onset heart failure with the gene expression level of step (a);
h) determining risk assessment and prognosis with the gene expression level of step (a);
i) determining risk prediction of progression and deterioration of cardiac function in patients with heart failure with the gene expression level of step (a);
j) monitoring heart health after therapy with the gene expression level of step (a);
k) monitoring heart health after positively responding to medical treatment, wherein there is a reduction of ischemic injury by treatment with lower gene expression level of step (a); and
l) monitoring heart health after a lack of response to medical treatment, wherein there is no reduction of ischemic injury by treatment with elevated gene expression level of step (a).

### Claim 17 (depends on 1)

The method of claim 1, wherein assaying the sample for one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence and Nourin protein monitors patients' heart health in clinical trials to determine improvement or deterioration, wherein high gene expression level of genes selected from the group consisting of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof, predicts myocardial cell damage in response to drug-testing by comparing each patient's baseline gene expression to circulating levels throughout drug testing, wherein an increase in gene expression level is indicative of cardiac toxicity, and wherein no increase in gene expression level is indicative of lack of cardiac toxicity.

### Claim 18 (depends on 1)

The method of claim 1, wherein assaying the sample for one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence and Nourin protein determines severity of myocardial ischemia in patients undergoing cardiac surgery and procedures for relief from ischemia, comprising:
a) determining severity of heart damage after myocardial ischemia;
b) assaying the sample before cardiac surgery obtained from patients with myocardial ischemia of step (a) for gene expression level of one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence selected from the group consisting of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof;
c) determining severity of myocardial injury in patients before cardiac surgery, wherein, high gene expression level in step (b) is indicative of severe myocardial injury, moderate gene expression level in step (b) is indicative of moderate myocardial injury, and low gene expression level in step (b) is indicative of low myocardial injury;
d) assaying a sample obtained from patients after cardiac surgery for gene expression level of one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence selected from the group consisting of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof;
e) determining severity of myocardial injury in patients after cardiac surgery, wherein, low gene expression level in step (d) after surgery is indicative of effective surgery and relief from ischemia, and high gene expression level in step (d) after surgery is indicative of ineffective surgery with no relief from ischemia;
f) identifying patients with moderate to severe ischemia by assaying a sample from said patients for gene expression level of one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence selected from the group consisting hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof, who will benefit from cardiac surgery and invasive percutaneous coronary intervention before conducting the procedure;
g) screening transplanted hearts for cardiac allograft inflammation and injury in patients by assaying a sample from said patients for gene expression level of one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence selected from the group consisting of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof, wherein, high gene expression level is indicative of severe inflammation and injury;
h) measuring circulating gene expression in a patient by assaying a sample from said patients for gene expression level of one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence selected from the group consisting of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof, to reduce the repeated invasive heart biopsy procedures after heart transplantation in said patients;
i) monitoring heart health of patients recovering after surgery by assaying a sample from said patients for gene expression level of one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence selected from the group consisting of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof; and
j) identifying individuals responding to surgical treatments by assaying a sample from said individuals for gene expression level of one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence selected from the group consisting of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof, wherein low gene expression level indicates responders to the surgical treatments, and high gene expression level indicates non-responders to the surgical treatments.

### Claim 19 (depends on 1)

The method of claim 1, wherein assaying the sample for one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence and Nourin protein detects a subject who is experiencing coronary artery disease, unstable angina, acute myocardial infarction (STEMI and NSTEMI), ACS or heart failure, comprising:
a) assaying a sample from the subject for gene expression level of one or more of a Nourin gene-based RNA molecular network of biomarkers related to the Nourin peptide sequence selected from the group consisting of hsa-miRNA-137, hsa-miRNA-106b, mRNA-FTHL-17, mRNA-ANAPC11, Nourin gene, and combination thereof, and Nourin protein;
b) identifying a subject who is experiencing coronary artery disease, wherein high gene expression of step (a) in the subject is observed with a positive ECHO/ECG Treadmill stress test before and after the test detecting coronary artery disease, and a very low gene expression is observed with a negative ECHO/ECG Treadmill stress test before and after the test detecting non-angina subjects;
c) differentiating a subject who experienced unstable angina from a subject who acute myocardial infarction, wherein the gene expression level of step (a) is much higher in acute myocardial infarction than unstable angina;
d) differentiating a subject who experienced heart failure from a healthy subject, wherein the gene expression level of step (a) is much higher in heart failure than non-ischemic healthy; and
e) differentiating a subject who experienced coronary artery disease, unstable angina, acute myocardial infarction, heart failure, based on the gene expression level of step (a) with no interference in the assay by the non-specific inflammatory marker, CRP,
wherein the sample from the subject consists of fresh blood, frozen blood, serum, plasma, saliva, urine, and tissue biopsies.
